المؤلفون: Farinazzo E, Dianzani C, Zalaudek I, Conforti C, Grabbe S, Goldust M

المصدر: Clinical, Cosmetic and Investigational Dermatology, Vol Volume 14, Pp 991-997 (2021)

مصطلحات موضوعية: covid-19, skin rashes, sars-cov-2, cutaneous manifestations, Dermatology, RL1-803

الوصف: Eleonora Farinazzo,1 Caterina Dianzani,2 Iris Zalaudek,1 Claudio Conforti,1 Stephan Grabbe,3 Mohamad Goldust3 1Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy; 2Dermatology Section, Department of Plastic, Reconstructive and Cosmetic Surgery, Campus Biomedico University Hospital, Rome, Italy; 3Department of Dermatology, University Medical Center Mainz, Mainz, GermanyCorrespondence: Mohamad GoldustDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University, Mainz, GermanyTel +49 1786-97-425Fax +49 6131-17-6629Email mgoldust@uni-mainz.deAbstract: The incidence of coronavirus disease 2019 (COVID-19)-related skin manifestations has progressively grown, in parallel with the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreading. The available evidence indicates that cutaneous signs are heterogeneous and can be divided as follows: a) erythematous rashes, b) lesions of vascular origin, c) vesicular rashes, d) urticarial rashes, and e) acute generalized exanthematous pustulosis (AGEP), erythema multiforme (EM) and other polymorphic/atypical reactions. Most cutaneous manifestations appear simultaneously or after respiratory and/or systemic symptoms such as fever, even if rarely urticaria has been reported as the first sign of the disease. It has been proposed that erythematous and vesicular rashes, as well as urticaria, are the result of immunological activation against Sars-CoV-2, similarly to other viral exanthems; alternatively, reactivation or co-infection of herpesviruses and drug hypersensitivity represent possible etiologic diagnosis that has to be considered. Regarding lesions of vascular origin, ischemic ones are the result of systemic hypercoagulability established in severe infections, whereas chilblains seem to be linked to the type I-interferon massively produced to halt virus replication. AGEP is triggered by drugs, whereas EM could represent a delayed immune response to the virus or a hypersensitivity reaction to drugs elicited by the inflammatory process built to fight the infection. A further pathogenic hypothesis is that the virus, or its particles detected in the skin (particularly in endothelium and eccrine glands), could be responsible for certain skin reactions, including chilblains and EM. From the available data, it appears that chilblains are correlated with younger age and less severe disease, while ischemic manifestations occur in the elderly with severe infection. In conclusion, larger studies are needed to confirm the suggested pathogenetic mechanisms of COVID-19-related skin reactions and to determine the potential prognostic significance of each one.Keywords: COVID-19, skin rashes, SARS-CoV-2, cutaneous manifestations

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/synthesis-of-the-data-on-covid-19-skin-manifestations-underlying-mecha-peer-reviewed-fulltext-article-CCIDTest; https://doaj.org/toc/1178-7015Test

الوصول الحر: https://doaj.org/article/f8ed4341148c4b51af2e6c4d2f4af552Test

المؤلفون: Neagu N., Dianzani C., Venuti A., Bonin S., Voidăzan S., Zalaudek I., Conforti C.

المساهمون: Neagu, N., Dianzani, C., Venuti, A., Bonin, S., Voidăzan, S., Zalaudek, I., Conforti, C.

مصطلحات موضوعية: HPV, keratinocyte skin cancer, actinic keratose, squamous cell carcinoma, Bowen’s disease, keratoacanthoma

الوصف: Keratinocyte skin cancers are the most frequent malignancy, accounting for approximately 30% of all cancers. Although beta genus HPV are the main etiologic agents for squamous cell carcinoma development in patients with epidermodysplasia verruciformis and organ transplant recipients, their role in non-melanoma skin cancer (NMSC) progression in the general population remains controversial. The aim of our review is to summarize current scientific data and to systematically analyze evidence regarding the role of HPV in keratinocyte skin cancers. A total of 2284 patients were included, of which 724 with actinic keratoses, 290 with Bowen’s disease, 949 with cutaneous squamous cell carcinomas and 321 with keratoacanthomas. In the case of actinic keratoses, the majority were positive for beta (n=372, 58.49%) and gamma HPV (n=256, 40.25%) and only a few (n=6, 0.94%) were positive for alpha subtypes. Similarly, most of the cutaneous squamous cell carcinomas were positive for beta (n=248, 55.98%) and gamma HPV (n=172, 33.82%) and 23 cases (2.42%) were positive for alpha subtypes. Bowen’s disease lesions were mostly positive for beta (n=43, 55.84%) and alpha HPV (n=30, 38.96%), in contrast to the gamma genus (n=4, 5.19%). Keratoacanthomas showed a high distribution among beta genus (n=79, 50.31%) and an equal proportion between alpha (n=39, 24.84%) and gamma (n=39, 24.84%) genera. Studies published so far identifying HPV in keratinocyte skin cancers reflect the difference in detection methods rather than a type-specific tendency towards either actinic keratoses, Bowen’s disease, squamous cell carcinoma, or keratoacanthoma. On the other hand, recent evidence regarding the role of HPV vaccination in patients with no-melanoma skin cancer brings into perspective the idea of a beta HPV vaccine or a combined alpha and beta HPV vaccine that could be used as an adjuvant treatment measure in patients with recalcitrant non-melanoma skin cancer.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36000380; info:eu-repo/semantics/altIdentifier/wos/WOS:000849751100001; volume:37; issue:1; firstpage:40; lastpage:46; numberofpages:7; journal:JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY; https://hdl.handle.net/11368/3046580Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85137194344

الإتاحة: https://doi.org/10.1111/jdv.18548Test
https://hdl.handle.net/11368/3046580Test

المؤلفون: Boggio E., Gigliotti C. L., Stoppa I., Pantham D., Sacchetti S., Rolla R., Grattarola M., Monge C., Pizzimenti S., Dianzani U., Dianzani C., Battaglia L.

المساهمون: Boggio E., Gigliotti C.L., Stoppa I., Pantham D., Sacchetti S., Rolla R., Grattarola M., Monge C., Pizzimenti S., Dianzani U., Dianzani C., Battaglia L.

مصطلحات موضوعية: cancer therapy, nanocarrier, polychemotherapy

الوصف: The most important limitations of chemotherapeutic agents are severe side effects and the development of multi-drug resistance. Recently, the clinical successes achieved with immunotherapy have revolutionized the treatment of several advanced-stage malignancies, but most patients do not respond and many of them develop immune-related adverse events. Loading synergistic combinations of different anti-tumor drugs in nanocarriers may enhance their efficacy and reduce life-threatening toxicities. Thereafter, nanomedicines may synergize with pharmacological, immunological, and physical combined treatments, and should be increasingly integrated in multimodal combination therapy regimens. The goal of this manuscript is to provide better understanding and key considerations for developing new combined nanomedicines and nanotheranostics. We will clarify the potential of combined nanomedicine strategies that are designed to target different steps of the cancer growth as well as its microenvironment and immunity interactions. Moreover, we will describe relevant experiments in animal models and discuss issues raised by translation in the human setting.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36986798; volume:15; issue:3; firstpage:937; lastpage:961; numberofpages:25; journal:PHARMACEUTICS; https://hdl.handle.net/2318/1899032Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85151644215

الإتاحة: https://doi.org/10.3390/pharmaceutics15030937Test
https://hdl.handle.net/2318/1899032Test

المؤلفون: Azzimonti B., Ballacchino C., Zanetta P., Cucci M. A., Monge C., Grattarola M., Dianzani C., Barrera G., Pizzimenti S.

المساهمون: Azzimonti B., Ballacchino C., Zanetta P., Cucci M.A., Monge C., Grattarola M., Dianzani C., Barrera G., Pizzimenti S.

مصطلحات موضوعية: basal cell carcinoma, keratinocyte carcinoma, melanoma, microbiota, oxidative stre, skin cancer, squamous cell carcinoma

الوصف: Mounting evidence indicates that the microbiota, the unique combination of micro-organisms residing in a specific environment, plays an essential role in the development of a wide range of human diseases, including skin cancer. Moreover, a persistent imbalance of microbial community, named dysbiosis, can also be associated with oxidative stress, a well-known emerging force involved in the pathogenesis of several human diseases, including cutaneous malignancies. Although their interplay has been somewhat suggested, the connection between microbiota, oxidative stress, and skin cancer is a largely unexplored field. In the present review, we discuss the current knowledge on these topics, suggesting potential therapeutic strategies.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36978794; info:eu-repo/semantics/altIdentifier/wos/WOS:000957152300001; volume:12; issue:3; firstpage:546; lastpage:567; numberofpages:22; journal:ANTIOXIDANTS; https://hdl.handle.net/2318/1899052Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85151513261

الإتاحة: https://doi.org/10.3390/antiox12030546Test
https://hdl.handle.net/2318/1899052Test

المؤلفون: Cucci M. A., Grattarola M., Monge C., Roetto A., Barrera G., Caputo E., Dianzani C., Pizzimenti S.

المساهمون: Cucci M.A., Grattarola M., Monge C., Roetto A., Barrera G., Caputo E., Dianzani C., Pizzimenti S.

مصطلحات موضوعية: A375 cell line, BRAFi/MEKi, D4M cell line, DUB3, Nrf2, YAP, dabrafenib, melanoma, targeted therapy resistance, trametinib

الوصف: The use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients has significantly improved progression-free and overall survival of metastatic melanoma patients. Nevertheless, half of the patients still develop resistance within the first year of therapy. Therefore, understanding the mechanisms of BRAFi/MEKi-acquired resistance has become a priority for researchers. Among others, oxidative stress-related mechanisms have emerged as a major force. The aim of this study was to evaluate the contribution of Nrf2, the master regulator of the cytoprotective and antioxidant response, in the BRAFi/MEKi acquired resistance of melanoma. Moreover, we investigated the mechanisms of its activity regulation and the possible cooperation with the oncogene YAP, which is also involved in chemoresistance. Taking advantage of established in vitro melanoma models resistant to BRAFi, MEKi, or dual resistance to BRAFi/MEKi, we demonstrated that Nrf2 was upregulated in melanoma cells resistant to targeted therapy at the post-translational level and that the deubiquitinase DUB3 participated in the control of the Nrf2 protein stability. Furthermore, we found that Nrf2 controlled the expression of YAP. Importantly, the inhibition of Nrf2, directly or through inhibition of DUB3, reverted the resistance to targeted therapies.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37372043; info:eu-repo/semantics/altIdentifier/wos/WOS:001016848000001; volume:12; issue:6; firstpage:1313; lastpage:1336; numberofpages:24; journal:ANTIOXIDANTS; https://hdl.handle.net/2318/1923070Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85163850577

الإتاحة: https://doi.org/10.3390/antiox12061313Test
https://hdl.handle.net/2318/1923070Test

المؤلفون: Piccolo, D., Zalaudek, I., Genovesi, C., Dianzani, C., Crisman, G., Fusco, I., Conforti, C.

المصدر: Annales de Dermatologie et de Vénéréologie ; volume 150, issue 2, page 121-122 ; ISSN 0151-9638

مصطلحات موضوعية: Dermatology

الإتاحة: https://doi.org/10.1016/j.annder.2022.09.007Test
https://api.elsevier.com/content/article/PII:S015196382200093X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S015196382200093X?httpAccept=text/plainTest

المؤلفون: Conforti C., Retrosi C., Agozzino M., Dianzani C., Nardon E., Oliveri A., Azzalini E., Guida S., Pellacani G., Di Lella G., Rongioletti F., Zalaudek I., Bonin S.

المساهمون: Conforti, C., Retrosi, C., Agozzino, M., Dianzani, C., Nardon, E., Oliveri, A., Azzalini, E., Guida, S., Pellacani, G., Di Lella, G., Rongioletti, F., Zalaudek, I., Bonin, S.

مصطلحات موضوعية: Bowen’s disease, human papillomavirus, keratinocyte skin tumors, squamous-cell carcinoma

الوصف: This comprehensive study delves into the intricate landscape surrounding the role of human papillomavirus (HPV) in extragenital keratinocyte skin tumors, specifically exploring Bowen’s disease (BD) and in situ squamous-cell carcinoma (iSCC). Through a multifaceted examination, this research study elucidates the nuanced interplay of HPV, gender dynamics, anatomical site variations, and potential implications for the etiopathogenesis of these malignancies.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:001172493100001; volume:13; issue:4; journal:JOURNAL OF CLINICAL MEDICINE; https://hdl.handle.net/20.500.11768/159380Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85187274531

الإتاحة: https://doi.org/20.500.11768/159380Test
https://doi.org/10.3390/jcm13041091Test
https://hdl.handle.net/20.500.11768/159380Test

المؤلفون: Conforti C., Guida S., Dianzani C., Turco P., Cazzato V., Zalaudek I., Piccolo D.

المساهمون: Conforti, C., Guida, S., Dianzani, C., Turco, P., Cazzato, V., Zalaudek, I., Piccolo, D.

مصطلحات موضوعية: acne, carbon peel, laser, rejuvenation, wrinkles

الوصف: Carbon peel laser treatment has been described for the improvement of skin texture, with pore reduction and acne lesion treatment. The technique consists of applying a carbon mask to the face for about ten minutes followed by laser irradiation with a Q-switched 1064 nm laser. This mechanism of action seems to be related to small carbon molecules binding both the corneocytes and serum within the hair follicles; the effect of the laser eliminates carbon bound to skin particles and the high temperature generated reduces sebum production by sebaceous glands and inhibits Cutibacterium acnes replication. Although this method was described 20 years ago, scientific data supporting its efficacy and safety have only recently been reported in small case series. For this reason, we performed a retrospective study including patients treated from January to May 2022 in the context of a private practice. Even if this study is limited by the low number of patients and its retrospective nature, this is the first research to show that carbon peel laser, performed with a standardized technique, is an effective and safe treatment for patients with acne lesions, showing pores and wrinkles, and is able to improve the overall skin aspect.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36422207; info:eu-repo/semantics/altIdentifier/wos/WOS:000895271200001; volume:58; issue:11; numberofpages:4; journal:MEDICINA; https://hdl.handle.net/20.500.11768/155690Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85142651164; https://www.mdpi.com/1648-9144/58/11/1668Test

الإتاحة: https://doi.org/20.500.11768/155690Test
https://doi.org/10.3390/medicina58111668Test
https://hdl.handle.net/20.500.11768/155690Test
https://www.mdpi.com/1648-9144/58/11/1668Test

المؤلفون: Toffoli L., Farinazzo E., Zelin E., Agozzino M., Dianzani C., Di Meo N., Nan K., Zalaudek I., Conforti C.

المساهمون: Toffoli, L., Farinazzo, E., Zelin, E., Agozzino, M., Dianzani, C., Di Meo, N., Nan, K., Zalaudek, I., Conforti, C.

مصطلحات موضوعية: Dupilumab, itching, prurigo nodularis, atopic dermatitis

الوصف: Prurigo nodularis (PN) is a debilitating chronic disease characterized by intense itching and excoriated hyperkeratotic nodules distributed on the trunk and extremities, especially the extensor surfaces. The pathophysiology includes complex and not yet well-understood mechanisms involving inflammation and dysregulation of the nervous system. Currently, there are no approved therapies by the Food and Drug Administration (FDA) and the few treatment approaches for this condition are often ineffective and related to severe side effects. An emerging therapeutic option is dupilumab, a monoclonal antibody for adults and adolescents with moderate-to-severe atopic dermatitis, that inhibits interleukin-4 receptor alpha subunit (IL4-Rα) and the signaling pathways activated by interleukin (IL)-4 and IL-13. These cytokines seem to be involved in the development and perpetuation of PN and other type-2 inflammation diseases. Data on this topic are limited, but the emergent positive effects of this drug, reported in the literature and summarized in this review, suggest that it can be a safe and efficient therapy in PN.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33588666; info:eu-repo/semantics/altIdentifier/wos/WOS:000618317700001; volume:33; issue:3; firstpage:1306; lastpage:1311; numberofpages:6; journal:THE JOURNAL OF DERMATOLOGICAL TREATMENT; http://hdl.handle.net/11368/2991683Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85100942696

الإتاحة: https://doi.org/10.1080/09546634.2021.1886232Test
http://hdl.handle.net/11368/2991683Test

المؤلفون: Neagu, N, Dianzani, C, Avallone, G, Dell'Aquila, C, Morariu, S-H, Zalaudek, I, Conforti, C

المساهمون: Neagu, N, Dianzani, C, Avallone, G, Dell'Aquila, C, Morariu, S-H, Zalaudek, I, Conforti, C

مصطلحات موضوعية: Human, Interleukin-4 Receptor alpha Subunit, Severity of Illness Index, Treatment Outcome, Antibodies, Monoclonal, Humanized, Dermatitis, Atopic

الوصف: Atopic dermatitis (AD) is a chronic, inflammatory skin disorder that most frequently occurs in children, but it can also affect adults. Even though most AD cases can be managed with topical treatments, moderate-to-severe forms require systemic therapies. Dupilumab is the first human monoclonal antibody approved for the treatment of AD. Its action is through IL-4 receptor alpha subunit inhibition, thus blocking IL-4 and IL-13 signaling pathways. It has been shown to be an effective, well-tolerated therapy for AD, as well as for asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and eosinophilic esophagitis (EoE). However, an increasing incidence of dupilumab-induced ocular surface disease (DIOSD) has been reported in patients treated with dupilumab, as compared to placebo. The aim of this study was to summarize scientific data regarding DIOSD in AD patients treated with dupilumab. A search of PubMed and clinicaltrials.gov databases was performed. There was no limit to study design. All AD cases were moderate-to-severe. DIOSD was either dermatologist-, allergist-, or ophthalmologist-assessed. Evidence shows that DIOSD occurs most frequently in patients with atopic dermatitis and not in other skin conditions, neither in patients with asthma, CRSwNP, nor EoE who are on dupilumab treatment. Further studies are warranted in order to establish a causal relationship between dupilumab and ocular surface disease. Nevertheless, ophthalmological evaluations prior to dupilumab initiation can benefit AD patients with previous ocular pathology or current ocular symptomatology. Also, patch testing for ocular allergic contact dermatitis might be advantageous in patients with a history of allergic conjunctivitis. Furthermore, TARC, IgE, and circulating eosinophils levels might be important biomarkers for a baseline assessment of future candidates to dupilumab treatment. However, TARC measurements should be resumed for research purposes only.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35122335; info:eu-repo/semantics/altIdentifier/wos/WOS:000756714100001; volume:36; issue:6; firstpage:820; lastpage:835; numberofpages:16; journal:JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY; http://hdl.handle.net/11368/3027626Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85124727577

الإتاحة: https://doi.org/10.1111/jdv.17981Test
http://hdl.handle.net/11368/3027626Test